Stock 1AD ADALTA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials AdAlta Limited

Equities

1AD

AU0000001AD2

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 07:10:47 10/05/2024 BST 		5-day change 1st Jan Change
0.023 AUD 0.00% Intraday chart for AdAlta Limited -14.81% -4.17%
04-29 AdAlta Secures Up to AU$3.7 Million for MOU, i-body Programs MT
04-08 AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market MT

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 37.68 24.09 13.94 30.65 16.97 8.8
Enterprise Value (EV) 1 35.38 18.54 12.76 26.54 12.31 8.025
P/E ratio -9.72 x -3.2 x -2.32 x -5.2 x -2.48 x -1.57 x
Yield - - - - - -
Capitalization / Revenue 18.7 x 6.81 x 3.64 x 7.69 x 6.16 x 2.54 x
EV / Revenue 17.5 x 5.24 x 3.33 x 6.66 x 4.47 x 2.31 x
EV / EBITDA -9.17 x -3.11 x -2.2 x -4.93 x -2.06 x -1.66 x
EV / FCF -14.2 x -4.86 x -3.5 x -9.6 x -6.14 x -2.46 x
FCF Yield -7.04% -20.6% -28.6% -10.4% -16.3% -40.6%
Price to Book 9.25 x 3.22 x 3.76 x 4.8 x 3.15 x 4.61 x
Nbr of stocks (in thousands) 101,846 150,569 163,946 245,176 314,185 366,680
Reference price 2 0.3700 0.1600 0.0850 0.1250 0.0540 0.0240
Announcement Date 06/09/18 29/08/19 27/08/20 27/08/21 28/08/22 25/08/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 2.02 3.539 3.828 3.984 2.754 3.469
EBITDA 1 -3.859 -5.957 -5.798 -5.389 -5.966 -4.841
EBIT 1 -3.862 -5.989 -5.84 -5.418 -5.999 -4.871
Operating Margin -191.17% -169.24% -152.57% -135.99% -217.85% -140.42%
Earnings before Tax (EBT) 1 -3.855 -5.918 -6.006 -5.628 -6.061 -4.851
Net income 1 -3.855 -5.918 -6.006 -5.628 -6.061 -4.851
Net margin -190.82% -167.24% -156.92% -141.26% -220.11% -139.84%
EPS 2 -0.0381 -0.0500 -0.0366 -0.0240 -0.0218 -0.0152
Free Cash Flow 1 -2.491 -3.811 -3.647 -2.764 -2.005 -3.258
FCF margin -123.29% -107.7% -95.29% -69.37% -72.82% -93.9%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 06/09/18 29/08/19 27/08/20 27/08/21 28/08/22 25/08/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 2.31 5.56 1.18 4.1 4.66 0.78
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -2.49 -3.81 -3.65 -2.76 -2.01 -3.26
ROE (net income / shareholders' equity) -65.2% -102% -107% -112% -103% -133%
ROA (Net income/ Total Assets) -38.5% -54.5% -45% -42.4% -38.1% -33.1%
Assets 1 10 10.87 13.34 13.26 15.92 14.64
Book Value Per Share 2 0.0400 0.0500 0.0200 0.0300 0.0200 0.0100
Cash Flow per Share 2 0.0200 0.0400 0.0200 0.0200 0.0300 0.0100
Capex 1 0 0.17 0 0 0.03 0
Capex / Sales 0.16% 4.82% 0.06% 0.05% 0.92% 0.06%
Announcement Date 06/09/18 29/08/19 27/08/20 27/08/21 28/08/22 25/08/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ADALTA LIMITED Stock AdAlta Limited
-4.17% 8.09M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 1AD Stock
  4. Financials AdAlta Limited